Analysis of prostate bed motion using an endorectal balloon and cone beam computed tomography during postprostatectomy radiotherapy.

abstract：Background:This study was designed to research the potential function of lncRNA ANRIL in osteosarcoma (OS). Materials and methods:Quantitative real-time PCR, cell counting kit-8, wound healing assay, Transwell assay, flow cytometric analysis, caspase activity analysis, and Western blot were carried out. Results:ANRIL...

journal_title：OncoTargets and therapy

authors： Guan H,Mei Y,Mi Y,Li C,Sun X,Zhao X,Liu J,Cao W,Li Y,Wang Y

更新日期：2018-08-14 00:00:00

abstract：Background:Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the...

journal_title：OncoTargets and therapy

authors： Wang K,Ruan H,Xu T,Liu L,Liu D,Yang H,Zhang X,Chen K

更新日期：2018-05-28 00:00:00

abstract：Background:Renal cell cancer (RCC) is one of the most lethal malignancies of the kidney in adults. mTOR (mammalian target of rapamycin) signaling pathway plays a pivotal role in RCC tumorigenesis and progression and inhibitors targeting the mTOR pathway have been widely used in advanced RCC treatment. Therefore, it is ...

journal_title：OncoTargets and therapy

authors： Zhu X,Xu A,Zhang Y,Huo N,Cong R,Ma L,Chu Z,Tang Z,Kang X,Xian S,Xu X

更新日期：2020-10-15 00:00:00

abstract：:Lymphangioleiomyomatosis (LAM) is a rare disease that generally affects young women and involves the abnormal proliferation of smooth muscle-like cells (LAM cells) in the lungs (pulmonary LAM) and extrapulmonary sites (extrapulmonary LAM). This disease is rare in males. It is hard to distinguish between lung cancer an...

journal_title：OncoTargets and therapy

authors： Liu Y,Guo Z,Zhao C,Li X,Liu H,Chen J

更新日期：2018-08-31 00:00:00

abstract：BACKGROUND AND PURPOSE:Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea i...

journal_title：OncoTargets and therapy

authors： Huo Z,Yu S,Hong S,Cao X,Xiu L,Liao Z,Li Y,Xiao H

更新日期：2016-06-20 00:00:00

abstract：Background:Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients' outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeutic window may exist ...

journal_title：OncoTargets and therapy

authors： Fleisher B,Ait-Oudhia S

更新日期：2017-12-27 00:00:00

abstract：BACKGROUND:Permanent prostate brachytherapy (PPB) is an effective treatment choice for low and intermediate risk prostate cancer (PCa). However, the impact of PPB on tumor immune status is still poorly understood. This study aimed to assess the immune status in PCa patients before and at different time points after PPB...

journal_title：OncoTargets and therapy

authors： Du E,Wang L,Li CY,Zhang CW,Qu YC,Liu RL,Xu Y,Yang K,Zhang ZH

更新日期：2017-05-15 00:00:00

abstract：:[This retracts the article on p. 1997 in vol. 9, PMID: 27103825.][This retracts the article on p. 841 in vol. 28.]. ...

journal_title：OncoTargets and therapy

authors：

更新日期：2016-09-20 00:00:00

abstract：BACKGROUND:Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has been reported to be a comparable alternative therapy to surgery for patients with T1-3N0M0 non-small cell lung cancer (NSCLC). However, it has not been clarified whether SBRT/SABR is as effective as surgery. We conducted t...

journal_title：OncoTargets and therapy

authors： Li M,Yang X,Chen Y,Yang X,Dai X,Sun F,Zhang L,Zhan C,Feng M,Wang Q

更新日期：2017-06-07 00:00:00

abstract：Background and Objectives:Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation demonstrate only a median progression-free survival (PFS) of 8 to 10 months and undergo EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. For decades, bilirubin has been reported to be assoc...

journal_title：OncoTargets and therapy

authors： Geng Y,Mei Y,Xi Y,Yu J,Meng K,Zhang T,Ma W

更新日期：2020-10-29 00:00:00

abstract：Purpose:Gastric carcinoma is the second most frequently diagnosed cancer and leading cause of cancer death in China. As a new generation of cancer therapeutic drug, CL-6, a curcumin derivative, shows better bioavailability than curcumin, which has shown anticancer effects in gastric cancer (GC). However, whether CL-6 s...

journal_title：OncoTargets and therapy

authors： Ye C,Wang W,Xia G,Yu C,Yi Y,Hua C,Tu F,Shen L,Chen C,Sun W,Zheng Z

更新日期：2019-03-27 00:00:00

abstract：BACKGROUND:Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC). This study assessed the relationship betwee...

journal_title：OncoTargets and therapy

authors： Beauchemin C,Cooper D,Lapierre MÈ,Yelle L,Lachaine J

更新日期：2014-06-18 00:00:00

abstract：BACKGROUND:Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors. Howeve...

journal_title：OncoTargets and therapy

authors： Sun B,Ding L,Wu S,Meng X,Song S

更新日期：2016-07-01 00:00:00

abstract：Purpose:Intraoperative identification of rectal cancer (RC) can be challenging, especially because of fibrosis after treatment with preoperative chemo- and radiotherapy (CRT). Tumor-targeted fluorescence imaging can enhance the contrast between tumor and normal tissue during surgery. Promising targets for RC imaging ar...

journal_title：OncoTargets and therapy

authors： Boogerd LS,van der Valk MJ,Boonstra MC,Prevoo HA,Hilling DE,van de Velde CJ,Sier CF,Fariña Sarasqueta A,Vahrmeijer AL

更新日期：2018-03-23 00:00:00

abstract：:Immune cells are essential for defending the body's balance and have increasingly been implicated in controlling tumor growth. In cervical cancer (CC), the immune landscape is extensively connected with human papillomavirus (HPV) status. Recent insights from studies have revealed that as a result of infection with HPV...

journal_title：OncoTargets and therapy

authors： Guo L,Hua K

更新日期：2020-08-12 00:00:00

abstract：Background:Exosomes are nano-sized biological vesicles released by many kinds of cells, which play an important role in tumor metastasis through transporting cytokines, RNAs and proteins. However, the molecular mechanisms of exosomes in hepatocellular carcinoma (HCC) metastasis are not completely understood. Materials...

journal_title：OncoTargets and therapy

authors： Qu Z,Feng J,Pan H,Jiang Y,Duan Y,Fa Z

更新日期：2019-08-23 00:00:00

abstract：Purpose:Strategies to increase radiosensitivity are urgently needed. Combining radiosensitizing reagents with radiotherapy could improve the outcome of cancer treatment. Some preclinical studies showed that sepantronium bromide (YM155) could sensitize cancer cells to radiation by inhibiting the survivin protein. In thi...

journal_title：OncoTargets and therapy

authors： Liu X,Zhao Y,Zhang W,Gao Y,Huo M,Liu M,Xiao Z,Liang S,Xu N,Zhu H

更新日期：2018-05-24 00:00:00

abstract：Background:Previous reports show that SIRT6 serves as a critical modulator of the development of multiple malignancies as well as other disorders. However, its role in nasopharyngeal carcinoma (NPC) is unknown. Thus, we elucidated the effects of SIRT6 on the survival of NPC cells, and modulation of cell death. Methods...

journal_title：OncoTargets and therapy

authors： Ouyang L,Yi L,Li J,Yi S,Li S,Liu P,Yang X

更新日期：2018-11-01 00:00:00

abstract：:Intrahepatic cholangiocarcinomas (IHCCs) are morphologically and biologically similar to pancreatic ductal adenocarcinomas (PDACs), so newly identified PDAC-associated genes or proteins could provide clues for screening novel biomarkers for IHCC. In this study, the expression of three novel PDAC tumor markers (T-box t...

journal_title：OncoTargets and therapy

authors： Zong M,Jia L,Li L

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...

journal_title：OncoTargets and therapy

authors： Cui X,Zhang J,Lv J,Yan Y,Liu X,Wang J,Lv Y,Zhang J

更新日期：2017-03-23 00:00:00

abstract：PURPOSE:This study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA). PATIENTS AND METHODS:By using the Surveillance, Epidemiology and End Results (SEER) registry, 1,917 patients with non-metastatic pCCA who underwent surgica...

journal_title：OncoTargets and therapy

authors： Leng KM,Liu YP,Wang ZD,Zhong XY,Liao GQ,Kang PC,Cui YF,Jiang XM

更新日期：2017-04-21 00:00:00

abstract：Purpose:B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro exper...

journal_title：OncoTargets and therapy

authors： Yang S,Yuan L,Wang Y,Zhu M,Wang J,Ke X

更新日期：2020-06-18 00:00:00

abstract：Objective:Multidrug resistance-associated protein 2 (MRP2), encoded by ABCC2 gene, is involved in the efflux of certain anticancer drugs. Here we observed whether the ABCC2 (G1249A) polymorphism impacts the transport abilities of MRP2-dependent paclitaxel, docetaxel, and doxorubicin in recombinant LLC-PK1 cell lines. ...

journal_title：OncoTargets and therapy

authors： Lian G,Yuan J,Gao Y

更新日期：2020-02-17 00:00:00

abstract：:Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment o...

journal_title：OncoTargets and therapy

authors： Recine F,Bongiovanni A,Riva N,Fausti V,De Vita A,Mercatali L,Liverani C,Miserocchi G,Amadori D,Ibrahim T

更新日期：2017-02-23 00:00:00

abstract：Purpose:Bulky non-small cell lung cancer (NSCLC) is difficult to achieve effective local control by conventionally fractionated radiotherapy (CRT). The present work aims to evaluate the safety and efficacy of partial stereotactic ablative boost radiotherapy (P-SABR) in bulky NSCLC. Patients and methods:From December 2...

journal_title：OncoTargets and therapy

authors： Bai Y,Gao XS,Qin SB,Chen JY,Su MM,Liu Q,Qin XB,Ma MW,Zhao B,Gu XB,Xie M,Cui M,Qi X,Li XY

更新日期：2018-05-08 00:00:00

abstract：OBJECTIVE:Although our previous studies have confirmed that 1, 3, 8-trihydroxy-6-methylant hraquinone (emodin) inhibits migration and invasion in epithelial ovarian cancer (EOC) cells, the underlying molecular mechanism remains unknown. Here, the aim was to investigate the effects of emodin on EOC cells and to study fu...

journal_title：OncoTargets and therapy

authors： Lu J,Xu Y,Zhao Z,Ke X,Wei X,Kang J,Zong X,Mao H,Liu P

更新日期：2017-07-19 00:00:00

abstract：Purpose:Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence continues to rise yearly. Photodynamic therapy (PDT) is a non-invasive form of cancer therapy, which utilizes the combined action of a photosensitizer, light, and oxygen molecules to selectively cause cellul...

journal_title：OncoTargets and therapy

authors： Shi S,Zheng G,Yang C,Chen X,Yan Q,Jiang F,Jiang X,Xin Y,Jiang G

更新日期：2019-12-31 00:00:00

abstract：BACKGROUND:Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therapy, we report on the o...

journal_title：OncoTargets and therapy

authors： Powles T,McFaul S,Stebbing J,Wilson P,Oliver T,Tranter N,Shamash J

更新日期：2008-09-01 00:00:00

abstract：:Background/Aims: MiR-145 and Smad2 have been widely reported in the development and progression of human malignancies. In the present study, we investigated the correlation between miR-145 and Smad2 in human glioblastoma multiforme (GBM). Methods: The epithelial-mesenchymal transition (EMT) biomarkers and Smad2 were a...

journal_title：OncoTargets and therapy

authors： Chen W,Huang B,Wang E,Wang X

更新日期：2019-04-23 00:00:00

abstract：OBJECTIVES:MicroRNA (miRNA)-related single-nucleotide polymorphisms (SNPs) in miRNA processing machinery genes can affect cancer risk, treatment efficacy, and patient prognosis. A miR-SNP of rs11077 located in the 3' untranslated region (3' UTR) of the miRNA processing machinery gene XPO5 was examined in 112 advanced n...

journal_title：OncoTargets and therapy

authors： Ding C,Li C,Wang H,Li B,Guo Z

更新日期：2013-07-11 00:00:00